Enjoy this podcast with Leonard Mazur, the co-founder, Chairman, and CEO of Citius Pharmaceuticals, a late-stage biopharma company focused on developing critical care. With over 50 years in the industry, there are many success lessons to be learned as Leonard has co-founded several companies, including Akrimax Pharmaceuticals and Genesis Pharmaceuticals, which he successfully sold to Pierre Fabre in 2003. DisclaimerThe information contained in this website and podcast arepurely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may beconstrued as a recommendation or endorsement of any of the companies discussed.Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Today we are honored to have Dr. Josep Bassaganya-Riera, President and CEO of NImmune Biopharma, to talk about how his company is leveraging computational modeling and bioinformatics to develop new therapeutics.DisclaimerThe information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
In this podcast, we are pleased to have Mike Walsh, CEO of Patient Advocacy Strategies as our guest. Patient advocacy may seem like a “nice to have” or an afterthought. In this podcast you’ll learn why the opposite is true – that it’s important to glean input from patient groups early on in the lifecycle and throughout the course of developing solutions for patients. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
It’s shocking that 106,000 people die every year from adverse drug reactions. Moreover, 350,000 people are hospitalized every year, 1.3 million people go to the ER, and it is the fourth leading cause of death in the United States. Adverse drug reactions are a behemoth problem, costing the economy almost half trillion dollars.DisclaimerThe information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
In this episode, filed at Science Square in Atlanta, we speak with David Francis and Mighten Yip of Palate Therapeutics, whose mission is to alter people’s food preferences away from sugary foods using therapeutic mouthwash. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
With over 1.5 million people suffering traumatic brain injuries a year, 80,000 stroke victims, and millions of concussions, the impact that brain impairment has on society is not to be ignored. We spoke with William Korinek of Astrocyte Pharmaceuticals, who is developing neuroprotein therapies for these conditions. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
There are 1.4 million meniscus procedures performed in the US and Europe every single year. Most of those are meniscetomy which is when the meniscus is removed. The problem is that once it is gone, so is the cushioning that protects the knee joint and cartilage, accelerating arthritis. A quarter of people continue to have pain after a few years. Millions of people have this procedure and it’s not the best answer. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Our guest today is Dr. Ivan Liachko, the CEO of Seattle-based Phase Genomics, a company whose core technology is ultra-long range genome sequencing. He’s also the founder of Genome Startup Day, dedicated to helping new biotech entrepreneurs transition from academic settings into industry and entrepreneurship. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Tune in for this insightful podcast with David Weinstock, the Vice President of Discovery Oncology at Merck, to find out what pharma investors really think when they are interviewing startups looking for funding. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Our guest today is another Atlanta luminary, Dr. Marvin Whiteley, the founder and CSO of SynthBiome, Inc. Deaths are expected to increase over the next 20-30 years due to antibiotic resistant infections. It’s common for people to go into the hospital for something innocuous, get an infection, and find that the bacterium doesn’t respond to antibiotic. There are strains infecting people outside of clinical settings, as well. As there are millions of deaths caused by this each year, the alarm bells are starting to go off because we are not developing a lot of new antibiotics. How can this trend be stopped? Disclaimers The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Carter Cliff is the CEO of Papillon Therapeutics. Papillon is advancing genetic medicines for life threatening conditions including Cystinosis, Friedreich's ataxia, Danon disease, and Alzheimer's disease, and the company is currently partnered with Novartis on a phase 1/2 trial for their lead candidate in cystinosis. Carter has a multi-decade career in biotech and life sciences and is also a venture partner at Saisei Ventures where he helps launch biotechnology companies, and has raised over $200MM in funding across various ventures. Enjoy the show! Disclaimers The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Today we’ve got Dr. Jonathan Arambula and Dr. Krystle Karoscik of InnovoTex, an oncology therapeutics company developing a platform of smart molecules capable of circumventing drug resistance often seen in treating ovarian cancer. They’re doing it in a safer way – hear about all this and more by listening to the show! Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
We’re going to talk with Peter Pitts, President of Center for Medicine in the Public Interest, about the IRA, which is impacting every company in biotech. The Inflation Reduction Act, or IRA, authorizes the price negotiation for a group of medicines selected by the government and, interestingly, allows no public pronouncements after the fact, by the companies. Disclaimers The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Today we’re excited to have Subh Roy who will share his insights about how to get funding for your biotech. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Dr. Dennis Liotta is very humble but don’t let that fool you – underneath the poised demeanor he’s a impassioned drug discovery giant who has made a significant contribution to improving the disease state of the world’s poor. The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Today we have four very special guests, some friends of mine, who are going to share with us the story behind all the momentum driving life sciences in Atlanta. · Eddie Lai represents the MetroAtlanta Chamber of Commerce · Courtney Law represents a group called Biolocity, which bridges Emory and Georgia Tech · Ryan Lawler is from Biosparks Labs, funded by Georgia Technology Ventures, supporting the life science community in Atlanta · Suna Lumeh is from a venture capital firm called Portal Innovations This was a great group so I hope you’ll listen to the show! Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Our guest today is Gaurav Byagathvalli, a Geoge Tech alum and the CEO of Piezo Therapeurtics, a company developing an innovative nucleic acid delivery platform for DNA and mRNA vaccines. Instead of using complicated equipment they use simplified circuits, analogous to what is in a lighter, to product the same impulse. They then use microneedles, which function as electrodes, to conduct those pulses into your skin resulting in highly targeted, localized delivery. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Our guest today is Nolan Townsend, the CEO of LEXEO Therapeutics, which focused on expanding the application of crisper gene therapies past rare diseases where they’ve generally been applied to more prevalent kinds of diseases. What got me excited for the talk was the enthusiasm that Nolan expressed for the application of genetic therapies to more common diseases, which is where all the costs live. This could have a very broad impact on society’s healthcare systems. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Today I am really excited to have Charles Gellman, CEO of HiDO Health. HiDO is a company that is focused on using artificial intelligence to help patients manage their medications for chronic disease. Each year, almost 250,000 in America die as a result of medical errors associated with lack of adherence to a prescription schedule, making it the third largest cause of death in the US. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
Our guest today is Dr. Amy Baxter, the CEO of Pain Care Labs, a company dedicated to using mechanical platforms such as vibrating devices to alleviate fear and pain associated with needles as well as reducing muscular skeletal pain in adults. Disclaimer The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.